Zacks Research Issues Negative Forecast for Hologic Earnings

Hologic, Inc. (NASDAQ:HOLX - Free Report) - Research analysts at Zacks Research cut their Q1 2025 earnings per share estimates for Hologic in a research note issued on Tuesday, December 31st. Zacks Research analyst R. Department now anticipates that the medical equipment provider will earn $1.01 per share for the quarter, down from their prior estimate of $1.02. The consensus estimate for Hologic's current full-year earnings is $4.28 per share. Zacks Research also issued estimates for Hologic's Q2 2025 earnings at $1.06 EPS, FY2025 earnings at $4.28 EPS, Q1 2026 earnings at $1.12 EPS, Q2 2026 earnings at $1.14 EPS, Q4 2026 earnings at $1.20 EPS, FY2026 earnings at $4.63 EPS, Q1 2027 earnings at $1.12 EPS and FY2027 earnings at $4.99 EPS.

Several other brokerages have also commented on HOLX. JPMorgan Chase & Co. lifted their price objective on Hologic from $92.00 to $94.00 and gave the stock an "overweight" rating in a report on Tuesday, November 5th. UBS Group boosted their price target on Hologic from $84.00 to $90.00 and gave the company a "neutral" rating in a research note on Tuesday, November 5th. Citigroup lowered shares of Hologic from a "buy" rating to a "neutral" rating and reduced their price target for the company from $95.00 to $85.00 in a research report on Tuesday, October 1st. Royal Bank of Canada raised their price objective on shares of Hologic from $86.00 to $89.00 and gave the stock a "sector perform" rating in a report on Tuesday, November 5th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $90.00 target price on shares of Hologic in a report on Thursday, December 19th. Six research analysts have rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $89.50.

Hologic Stock Performance

Shares of HOLX stock traded up $1.45 during trading hours on Friday, reaching $73.19. The company had a trading volume of 2,059,002 shares, compared to its average volume of 1,611,501. The firm has a market cap of $16.61 billion, a PE ratio of 21.98, a price-to-earnings-growth ratio of 2.32 and a beta of 0.96. The company has a debt-to-equity ratio of 0.49, a quick ratio of 3.03 and a current ratio of 3.69. The business has a fifty day moving average price of $76.72 and a 200-day moving average price of $78.44. Hologic has a one year low of $70.36 and a one year high of $84.67.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, hitting analysts' consensus estimates of $1.01. The company had revenue of $987.90 million during the quarter, compared to analyst estimates of $978.25 million. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The firm's revenue for the quarter was up 4.5% on a year-over-year basis. During the same period in the previous year, the business earned $0.89 EPS.

Insiders Place Their Bets

In other Hologic news, COO Essex D. Mitchell sold 24,856 shares of the business's stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total value of $1,897,507.04. Following the sale, the chief operating officer now owns 27,957 shares in the company, valued at $2,134,237.38. The trade was a 47.06 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 1.75% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Hologic

Several large investors have recently made changes to their positions in the company. Wolff Wiese Magana LLC bought a new position in shares of Hologic in the 3rd quarter valued at about $25,000. General Partner Inc. purchased a new stake in shares of Hologic in the fourth quarter worth approximately $26,000. First Horizon Advisors Inc. lifted its stake in shares of Hologic by 38.3% during the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider's stock worth $39,000 after acquiring an additional 134 shares during the last quarter. Sunbelt Securities Inc. purchased a new position in Hologic during the 2nd quarter valued at $37,000. Finally, Cromwell Holdings LLC grew its position in Hologic by 330.2% in the 3rd quarter. Cromwell Holdings LLC now owns 542 shares of the medical equipment provider's stock valued at $44,000 after acquiring an additional 416 shares during the last quarter. 94.73% of the stock is owned by institutional investors.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.